News

Blueprint Medicines gets more ducks in a row before CEO transition; Paul Stoffels has his work cut out for him at Gilead’s crumbling partner

Philina Lee → When Jeff Albers announced he would no longer be CEO of Blueprint Medicines, the leadership carousel at the Aykakit maker had yet to wind down. Yes, Kate Haviland is next in line […]

No Picture
Boston Cambridge Biotech Trending News

BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation

CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)—- $BGNE #BGNE–BeiGene announces an sNDA for BRUKINSA in first-line chronic lymphocytic leukemia has been accepted in China with breakthrough therapy designation. Click here to view original post

No Picture
News

Active Motif Incorporated Announces the Acquisition of Amaryllis Nucleics and their proprietary RNASeq workflow

CARLSBAD, Calif.: CARLSBAD, Calif., Jan. 27, 2022 /PRNewswire/ — Active Motif Incorporated, a company with the vision of bringing epigenetics more deeply into precision medicine, announced that it has purchased Amaryllis Nucleics, a Bay Area-based […]

No Picture
Boston Cambridge Biotech Trending News

ReForm Biologics Changes Name to Comera Life Sciences

WOBURN, Mass.–(BUSINESS WIRE)–ReForm Biologics, Inc., a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that the company has changed its name to Comera Life Sciences, […]

News

AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022

CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $AVRO–AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi […]